However, it remains unclear if the shorter overall survival of patients with low PSMA expressing metastases is due to dedifferentiated and more aggressive tumor phenotypes, or due to reduced efficacy of Lu-PSMA therapy. The gene discussed is FOLH1; the disease is neoplasm.